CLIAC Waiver Criteria Input Readied As FDA Gears Up To Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
The Clinical Laboratory Improvement Advisory Committee is close to issuing waiver recommendations, after agreeing to largely adopt criteria developed by its CLIA waiver workgroup
You may also be interested in...
Long-Awaited CLIA Draft Guidance Offers Some Leeway For Study Design
FDA's CLIA waiver application draft guidance could offer test sponsors added flexibility in designing clinical studies
Long-Awaited CLIA Draft Guidance Offers Some Leeway For Study Design
FDA's CLIA waiver application draft guidance could offer test sponsors added flexibility in designing clinical studies
CLIA-Waived Test Market Increasing As Public Health Concerns Loom
Rapid growth in the adoption of CLIA-waived laboratory tests is causing some unease regarding appropriate use of the tests